Few patients with diabetic kidney disease (DKD) are receiving guideline-recommended protective therapies, a new study suggests, highlighting missed opportunities to improve their care.
“We are experiencing a shifting landscape, with several new renoprotective treatments approved in the past few years, and potentially more to come in the near future,” Csaba Kovesdy, MD, of the University of Tennessee in Memphis, told Renal & Urology News. “Our data from 2018-2019 suggests that the application of ‘traditional’ renoprotective therapies is insufficient, which creates a significant unmet need for these newer therapies.”
